Kamada Ltd. Expands Plasma Collection Operations with New Center in San Antonio, TX
On March 19, 2025, Kamada Ltd., a leading global biopharmaceutical company specializing in the production of plasma-derived products for rare and serious conditions, announced the expansion of its plasma collection operations. The expansion includes the opening of a third plasma collection center, operated by Kamada’s wholly owned subsidiary, Kamada Plasma.
Details of the New Center
The new center, located in San Antonio, TX, spans over 11,100 square feet and is planned to support close to 50 donor beds. With an estimated total collection capacity of approximately 50,000 liters annually, this new facility will significantly contribute to Kamada’s production capabilities.
Impact on Kamada
This expansion is expected to strengthen Kamada’s position as a leading player in the specialty plasma-derived field. With the addition of the new center, the company will be able to increase its production capacity, ensuring a steady supply of its marketed products for rare and serious conditions. Moreover, the expansion also signifies Kamada’s commitment to investing in its infrastructure and research and development efforts to meet the growing demand for plasma-derived therapies.
Impact on Individuals
For individuals requiring plasma-derived therapies, this expansion is good news. The increased production capacity will ensure a more consistent and reliable supply of these essential treatments. Furthermore, the expansion may lead to the development of new plasma-derived therapies, as Kamada continues to invest in research and development.
Impact on the World
The plasma-derived therapy market is expected to grow significantly in the coming years due to the increasing prevalence of rare diseases and the aging population. Kamada’s expansion is a response to this growing demand and will contribute to the global supply of these essential therapies. Additionally, the company’s ongoing research and development efforts may lead to the discovery of new treatments for various conditions, potentially improving the lives of countless individuals worldwide.
Conclusion
In conclusion, Kamada Ltd.’s expansion of its plasma collection operations with the opening of a new center in San Antonio, TX, is a significant step forward for the company and the plasma-derived therapy market as a whole. This expansion will strengthen Kamada’s position as a leader in the field, ensure a more consistent and reliable supply of essential therapies, and contribute to ongoing research and development efforts. Ultimately, this expansion has the potential to significantly improve the lives of individuals with rare and serious conditions, both in the US and around the world.
- Kamada Ltd. announces the opening of a third plasma collection center in San Antonio, TX.
- The new center, operated by Kamada Plasma, will support close to 50 donor beds and have an estimated annual collection capacity of 50,000 liters.
- The expansion is expected to strengthen Kamada’s position as a leading player in the specialty plasma-derived field.
- The increased production capacity will ensure a more consistent and reliable supply of essential plasma-derived therapies.
- The expansion is a response to the growing demand for plasma-derived therapies due to the increasing prevalence of rare diseases and the aging population.
- Ongoing research and development efforts may lead to the discovery of new plasma-derived therapies.
